Quarterly ResultApr 22, 2026, 06:41 AM
Boston Scientific Q1 2026 Net Sales Hit $5.203B, EPS $0.90
AI Summary
Boston Scientific reported strong first-quarter 2026 results, with net sales reaching $5.203 billion, an 11.6% increase on a reported basis, meeting its guidance. GAAP net income attributable to common stockholders surged to $1.341 billion, or $0.90 per share, significantly up from the prior year. The company also achieved adjusted EPS of $0.80, at the high end of its guidance range, driven by robust growth across its Cardiovascular and MedSurg segments and all major regions. Additionally, the company announced positive clinical trial outcomes and regulatory approvals for key products.
Key Highlights
- Net sales grew 11.6% to $5.203 billion, meeting guidance.
- GAAP EPS increased to $0.90 from $0.45 year-over-year.
- Adjusted EPS reached $0.80, at the high end of guidance.
- Cardiovascular sales rose 13.5% and MedSurg sales 7.8% reported.
- Positive clinical trial results for WATCHMAN FLX, EKOS, and FARAPULSE.